BRAF inhibitors, such as PLX4032, which have been reported to upregulate PGC1α expression in melanomas (140, 141), inhibit metastasis partly by suppressing the Wnt/β-Catenin-MITF pathway and promoting the expression of PGC1α (125). Here, BRAF is linked to melanoma.